C3 ग्लोमेरुलोपैथी या प्राथमिक IC-MPGN के साथ 12–17 वर्ष के किशोरों में मेम्ब्रेनोप्रोलिफेरेटिव ग्लोमेरुलोनेफ्राइटिस का उपचार

References

1. In 2025, pegcetacoplan was also approved by the US Food and Drug Administration for the treatment of adult and pediatric patients aged $ 12 years with C3G or primary IC-MPGN to reduce proteinuria.
2. Adolescents (12–17 yrs old), n (%)
3. Pegcetacoplan is administered as a subcutaneous injection at a recommended dose of 1080 mg (in 20 ml) twice a week for adults using a commercially available infusion pump or on-body injector device, where available.
4. For both C3G and primary IC-MPGN, a ≥ 50% proteinuria reduction after 12 months has consistently been associated with significantly lower risk of kidney failure, as demonstrated by both the UK RaDaR and Spanish GLOSEN registries.
5. patients who achieve a UPCR < 0.88 g/g (< 100 mg/mmol) at 12 months after diagnosis benefit from a 90% lower risk of kidney failure than those who did not achieve this threshold.
6. In this context, even stabilization of eGFR may be considered a success after 6 months of complement inhibitor therapy, although it must be acknowledged that changes in eGFR are dependent on factors such as disease chronicity.